Neurofibromatosis



The Neurofibromatosis-associated Tumor Biobank


Condition:   Neurofibromatoses
Intervention:  
Sponsor:   Ren tingting
Not yet recruiting


Non-invasive Stimulation in Neurofibromatosis Type 1


Condition:   Neurofibromatosis 1
Intervention:   Other: Transcranial direct current stimulation
Sponsor:   University of Manchester
Recruiting


Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1


Conditions:   Neurofibromatosis 1;   Cutaneous Neurofibroma
Interventions:   Drug: Diclofenac Sodium;   Drug: Saline Solution
Sponsor:   Fundação Educacional Serra dos Órgãos
Completed


Photodynamic Therapy for Benign Dermal Neurofibromas


Condition:   NEUROFIBROMATOSIS 1
Intervention:   Procedure: PDT Treatment
Sponsor:   Harry T Whelan, MD
Recruiting


Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma


Condition:   Neurofibromatosis Type 1
Interventions:   Device: Magnetic resonance imaging;   Drug: Gadolinium contrast
Sponsors:   Washington University School of Medicine;   St. Louis Children's Hospital
Recruiting


Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)


Conditions:   Neurofibromatosis 1;   Plexiform Neurofibromas
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Recruiting


Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain


Conditions:   Neurofibromatosis Type 1;   Plexiform Neurofibromas
Intervention:   Behavioral: Acceptance and Commitment Therapy (ACT)
Sponsor:   National Cancer Institute (NCI)
Recruiting


Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery


Conditions:   Neurofibromatosis Type 1;   Plexiform Neurofibroma
Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Selumetinib
Sponsor:   National Cancer Institute (NCI)
Recruiting


Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T


Condition:   Neurofibromatosis 1
Intervention:   Drug: Everolimus
Sponsors:   The University of Texas Health Science Center, Houston;   Texas Neurofibromatosis Foundation
Completed


Effect of Lamotrigine on Cognition in NF1


Condition:   Neurofibromatosis Type 1
Interventions:   Drug: Lamotrigine;   Drug: Placebo
Sponsors:   Erasmus Medical Center;   Universitaire Ziekenhuizen Leuven;   ZonMw: The Netherlands Organisation for Health Research and Development
Recruiting


Internet Support Group for Parents of a Child With Neurofibromatosis Type 1


Condition:   Neurofibromatosis 1
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Completed


MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1


Condition:   Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
Intervention:   Drug: PD-0325901
Sponsor:   University of Alabama at Birmingham
Active, not recruiting


Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)


Condition:   Neurofibromatosis Type 1 (NF1)
Intervention:   Drug: Cholecalciferol
Sponsors:   University of Utah;   U.S. Army Medical Research and Materiel Command;   Universitätsklinikum Hamburg-Eppendorf;   University of British Columbia;   Children's Hospital Medical Center, Cincinnati
Recruiting


Neurofibromatosis (NF) Registry Portal


Conditions:   Neurofibromatosis 1;   Neurofibromatosis 2;   Schwannomatosis
Intervention:  
Sponsor:   The Children's Tumor Foundation
Recruiting


Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)


Condition:   Neurofibromatoses
Interventions:   Drug: Levulan (5-aminolevulinic acid) uptake.;   Drug: Levulan (5-aminolevulinic acid) photodynamic therapy.
Sponsor:   Harry T Whelan, MD
Active, not recruiting


Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain


Condition:   Neurofibromatosis
Intervention:   Behavioral: ACT Workshop
Sponsor:   National Cancer Institute (NCI)
Completed


Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients


Condition:   Neurofibromatosis 2
Intervention:   Drug: RAD001
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed


Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2


Condition:   Neurofibromatosis Type II
Intervention:   Drug: Everolimus (RAD001) , Afinitor®
Sponsors:   New York University School of Medicine;   Novartis Pharmaceuticals;   The Children's Tumor Foundation
Completed


Neurofibromatosis Type 1 Patient Registry


Condition:   Neurofibromatosis Type 1
Intervention:  
Sponsor:   Washington University School of Medicine
Completed


Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas


Conditions:   Neurofibromatosis;   Neurofibromas
Intervention:   Drug: Gleevec
Sponsor:   Kent Robertson
Completed


A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1


Condition:   Neurofibromatosis Type 1
Interventions:   Drug: Lovastatin ™;   Device: placebo
Sponsors:   University of Alabama at Birmingham;   Boston Children’s Hospital;   Children's Hospital of Philadelphia;   Children's Research Institute;   Children's Hospital Medical Center, Cincinnati;   National Cancer Institute (NCI);   University of Chicago;   University of Utah;   Washington University School of Medicine;   Sydney Children's Hospitals Network;   University of Texas Southwestern Medical Center
Completed


Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas


Conditions:   Neurofibromatosis Type I;   Plexiform Neurofibroma
Interventions:   Drug: Nexavar (BAY 43-9006) (Sorafenib);   Drug: Toxicity, Pharmacokinetics;   Drug: Pharmacodynamics;   Drug: Radiographic Evaluation;   Drug: QOL assessment, Neuropsychological;   Drug: Bony Toxicity
Sponsor:   National Cancer Institute (NCI)
Completed


A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas


Condition:   Neurofibromatosis Type 1
Intervention:   Drug: Sirolimus
Sponsors:   University of Alabama at Birmingham;   Boston Children’s Hospital;   Children's Hospital of Philadelphia;   Children's Research Institute;   Children's Hospital Medical Center, Cincinnati;   National Cancer Institute (NCI);   University of Chicago;   University of Utah;   Washington University School of Medicine
Completed


Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1


Conditions:   Neurofibromas;   Neurofibromatosis Type 1
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Completed


Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)


Conditions:   Neurofibromatosis Type I;   Legius Syndrome
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Active, not recruiting

Refine Your Search Advanced Search